Viking Therapeutics (VKTX) Non-Current Assets (2014 - 2026)

Viking Therapeutics has reported Non-Current Assets for 13 years, with the latest figure at $4.3 million in Q2 2026.

• Quarterly Non-Current Assets rose 419.66% year-over-year to $4.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.2 million (up 25.6% YoY) and the FY2025 annual result came in at $131000.0, down 88.14% from the prior year.
• Non-Current Assets climbed to $4.3 million in Q2 2026 per VKTX's latest filing, from $33000.0 in the prior quarter.
• Over five years, Non-Current Assets peaked at $4.3 million in Q2 2026 and troughed at $33000.0 in Q1 2026.
• A 5-year average of $1.3 million and a median of $1.3 million in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2026: Non-Current Assets soared 1011.19% in 2022, then tumbled 96.6% in 2026.
• Over 5 years, Non-Current Assets stood at $1.5 million in 2022, then dropped by 15.04% to $1.3 million in 2023, then declined by 12.65% to $1.1 million in 2024, then plunged by 88.14% to $131000.0 in 2025, then soared by 3208.4% to $4.3 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $4.3 million, $33000.0, and $131000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.